Atlas Bio came out of stealth with an $11M seed round led by Creandum; First Momentum invested at pre-seed.
OCT 27, 2026
Atlas Bio provides an AI foundation model of human biology that runs in silico clinical trials for immunology, predicting patient-level transcriptomic responses to treatments and comparing mechanisms, indications, and patient groups to inform biopharma clinical development and investment decisions
Atlas Bio provides an AI foundation model of human biology that runs in silico clinical trials for immunology, predicting patient-level transcriptomic responses to treatments and comparing mechanisms, indications, and patient groups to inform biopharma clinical development and investment decisions.